On July 8, 2024 Iktos, a company sepecialized in Artificial Intelligence (AI) and Robotics for new drug design, reported the acquisition of Synsight, a French biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates (Press release, Iktos, JUL 8, 2024, View Source [SID1234644709]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This acquisition brings significant advancements to Iktos’ drug discovery platform, now incorporating Synsight’s MT Bench technology for screening protein-protein and RNA-protein interactions (PPI and RPI). The merger also integrates automated biological testing into Iktos’ existing capabilities, which include generative AI design, retrosynthesis, and automated synthesis. This addition strengthens Iktos’ value chain by internalizing biological testing, accelerating the design-make-test process, and expanding drug discovery programs targeting critical disease mechanisms.

"This acquisition is an important milestone for Iktos", stated Yann Gaston-Mathé, co-founder and CEO of Iktos. "Iktos, a leader in AI-driven Drug Discovery, unlocks bottlenecks in challenging programs and accelerates identification of drug candidates. The acquisition of Synsight enables Iktos to expand its platform to new modulators of PPI’s and RPI’s, historically highly challenging targets, thereby addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases."